
Epidermolysis Bullosa - Pipeline Insight, 2025
Description
DelveInsight’s, “Epidermolysis Bullosa - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Epidermolysis Bullosa: Overview
Epidermolysis Bullosa, is a group of rare diseases that cause fragile, blistering skin. The blisters may appear in response to minor injury, even from heat, rubbing, scratching or adhesive tape. Blisters can form anywhere on the surface of the skin, within the oral cavity and in more severe forms may also involve the external surface of the eye, as well as the respiratory, gastrointestinal and genitourinary tracts.
Symptoms of Epidermolysis Bullosa includes: skin that blisters easily, blisters inside the mouth, blisters on the hands and soles of the feet, scarred skin, thickened skin and nails, skin that looks thin, tiny pimple-like bumps (milia), dental problems, such as tooth decay, and difficulty swallowing.
The type reflects where on the body the blistering takes place and which layer of skin is affected. There are mainly five types of epidermolysis bullosa:
There is no cure for Epidermolysis Bullosa. The current treatments for Epidermolysis Bullosa is are symptomatic cure. The primary aim is to protect the skin and stop blister formation, promote healing, and prevent complications. Research, including gene therapy and cell-based therapy are in clinical development to improve quality of life.
""Epidermolysis Bullosa - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Epidermolysis Bullosa pipeline landscape is provided which includes the disease overview and Epidermolysis Bullosa treatment guidelines. The assessment part of the report embraces, in depth Epidermolysis Bullosa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Epidermolysis Bullosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Epidermolysis Bullosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Epidermolysis Bullosa Emerging Drugs
Further product details are provided in the report……..
Epidermolysis Bullosa: Therapeutic Assessment
This segment of the report provides insights about the different Epidermolysis Bullosa drugs segregated based on following parameters that define the scope of the report, such as:
Epidermolysis Bullosa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Epidermolysis Bullosa therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Epidermolysis Bullosa drugs.
Epidermolysis Bullosa Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Epidermolysis Bullosa: Overview
Epidermolysis Bullosa, is a group of rare diseases that cause fragile, blistering skin. The blisters may appear in response to minor injury, even from heat, rubbing, scratching or adhesive tape. Blisters can form anywhere on the surface of the skin, within the oral cavity and in more severe forms may also involve the external surface of the eye, as well as the respiratory, gastrointestinal and genitourinary tracts.
Symptoms of Epidermolysis Bullosa includes: skin that blisters easily, blisters inside the mouth, blisters on the hands and soles of the feet, scarred skin, thickened skin and nails, skin that looks thin, tiny pimple-like bumps (milia), dental problems, such as tooth decay, and difficulty swallowing.
The type reflects where on the body the blistering takes place and which layer of skin is affected. There are mainly five types of epidermolysis bullosa:
- Epidermolysis bullosa simplex (EBS): It is the most common type, which tends to be milder with a low risk of serious complications.
- Dystrophic epidermolysis bullosa (DEB): This type of EB can range from mild to severe.
- Junctional epidermolysis bullosa (JEB): This type of EB is the rarest and is the most severe type.
- Kindler syndrome: This is a mixed condition, since blisters appear across different skin layers. It can also cause patchy changes in your skin coloring when it’s exposed to the sun.
There is no cure for Epidermolysis Bullosa. The current treatments for Epidermolysis Bullosa is are symptomatic cure. The primary aim is to protect the skin and stop blister formation, promote healing, and prevent complications. Research, including gene therapy and cell-based therapy are in clinical development to improve quality of life.
""Epidermolysis Bullosa - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Epidermolysis Bullosa pipeline landscape is provided which includes the disease overview and Epidermolysis Bullosa treatment guidelines. The assessment part of the report embraces, in depth Epidermolysis Bullosa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Epidermolysis Bullosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Epidermolysis Bullosa R&D. The therapies under development are focused on novel approaches to treat/improve Epidermolysis Bullosa.
This segment of the Epidermolysis Bullosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Epidermolysis Bullosa Emerging Drugs
- EB-101: Abeona Therapeutics
- INM-755: InMed Pharmaceuticals
- BM-3103: BioMendics
Further product details are provided in the report……..
Epidermolysis Bullosa: Therapeutic Assessment
This segment of the report provides insights about the different Epidermolysis Bullosa drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Epidermolysis Bullosa
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Epidermolysis Bullosa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Epidermolysis Bullosa therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Epidermolysis Bullosa drugs.
Epidermolysis Bullosa Report Insights
- Epidermolysis Bullosa Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Epidermolysis Bullosa drugs?
- How many Epidermolysis Bullosa drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Epidermolysis Bullosa?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Epidermolysis Bullosa therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Epidermolysis Bullosa and their status?
- What are the key designations that have been granted to the emerging drugs?
- Abeona Therapeutics
- InMed Pharmaceuticals
- BioMendics
- RHEACELL
- Castle Creek Biosciences
- BPGbio
- Eloxx Pharmaceuticals
- Phoenicis Therapeutics
- Aegle Therapeutics
- Amryt Pharma
- EB-101
- INM-755
- BM-3103
- APZ 2
- FCX-007
- BP 31510
- ZKN-013
- PTD-003
- AGLE-102
- AP-103
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Epidermolysis Bullosa: Overview
- Causes
- Etiology
- Signs and Symptoms
- Disease Treatment/Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Epidermolysis Bullosa– DelveInsight’s Analytical Perspective
- Late Stage Products (Registered)
- Comparative Analysis
- EB-101: Abeona Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- INM-755: InMed Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Epidermolysis Bullosa Key Companies
- Epidermolysis Bullosa Key Products
- Epidermolysis Bullosa- Unmet Needs
- Epidermolysis Bullosa- Market Drivers and Barriers
- Epidermolysis Bullosa- Future Perspectives and Conclusion
- Epidermolysis Bullosa Analyst Views
- Epidermolysis Bullosa Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.